Finding. Cavalcante, Caldeira da Silva, Vogt and Kowaltowski measure mitochondria in Parkinson’s hiPSC astrocytes and get two genotypes, not one disease. LRRK2 G2019S astrocytes hold less calcium and push it out more slowly after ATP. PRKN mutant astrocytes run a more oxidative respiratory program than the LRRK2 cells. Both fragment their mitochondria, move them to the periphery, change DRP1 phosphorylation, and lose respiratory-complex protein.
Why this paper matters
Parkinson’s research still defaults to the dopaminergic neuron. LRRK2 and parkin earned that habit: both proteins touch mitochondrial quality control. The glial half of the story is no longer optional. Astrocytes buffer calcium, feed neurons, and run their own OXPHOS. If those astrocytes are metabolically wrong, the neuron inherits a bad neighborhood.
Alicia Kowaltowski’s lab measures bioenergetics rather than staining for it. That matters here. The paper does not say “mitochondria look bad in PD glia.” It says LRRK2 mishandles calcium, PRKN runs a different oxidative tone, and both wreck morphology and complex abundance. Those are separable lesions. Drugs that restore parkin-linked mitophagy will not automatically fix LRRK2 calcium extrusion, and the reverse is also true.
What they actually measured
Human iPSC astrocytes from LRRK2 G2019S, PRKN (c.155delA; Ex3-4del), and wild-type controls. Fura-2 AM for cytosolic calcium: LRRK2 mutants were lower at baseline and slower to extrude calcium after ATP. MitoTracker Deep Red: both PD genotypes showed more fragmentation and a peripheral shift in mitochondrial distribution. Resipher continuous OCR: PRKN mutants were more oxidative than LRRK2 mutants. RT-qPCR and capillary westerns for calcium-transport and bioenergetic machinery showed altered DRP1 phosphorylation and lower respiratory-complex levels in both mutant lines versus control.
The design is straightforward and the split is the result.
How to read the score
This is core mitochondrial cell biology in a disease-relevant human glial model. Confidence is high for the abstract’s comparative claims. It is medium for pathogenesis. There is no neuron-killing assay in the abstract, no in vivo astrocyte replacement, and culture OCR is not a substantia nigra. Grouping two PRKN alleles is a convenience. The LRRK2 calcium defect is the cleanest genotype-specific finding; the shared fragmentation/complex-loss finding is the one most likely to be a final common path.
Score 88 is for a usable, genotype-split glial mitochondrial map.
What to do with it
If you model PD astrocytes, instrument calcium extrusion and OCR as separate endpoints and keep LRRK2 and PRKN in different bins. If you follow DRP1, this paper says phosphorylation state is already wrong in both genotypes — a shared dynamics handle. If you follow neuron-only LRRK2 kinase inhibitors, ask what those drugs do to astrocyte calcium and complex abundance. Do not treat “more oxidative” PRKN astrocytes as healthier; a hotter OCR can be compensation or a ROS engine. The abstract does not decide.